Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

Cited In for PubMed (Select 17277252)

1.

A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies.

Bartroff J, Lai TL, Narasimhan B.

Stat Med. 2014 Jul 20;33(16):2718-35. doi: 10.1002/sim.6124. Epub 2014 Feb 27.

PMID:
24577750
2.

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM.

Invest New Drugs. 2012 Aug;30(4):1660-70. doi: 10.1007/s10637-011-9724-3. Epub 2011 Jul 28.

3.

Randomized phase II trials: a long-term investment with promising returns.

Sharma MR, Stadler WM, Ratain MJ.

J Natl Cancer Inst. 2011 Jul 20;103(14):1093-100. doi: 10.1093/jnci/djr218. Epub 2011 Jun 27. Review.

4.

Patient education integrated with acupuncture for relief of cancer-related fatigue randomized controlled feasibility study.

Johnston MF, Hays RD, Subramanian SK, Elashoff RM, Axe EK, Li JJ, Kim I, Vargas RB, Lee J, Yang L, Hui KK.

BMC Complement Altern Med. 2011 Jun 25;11:49. doi: 10.1186/1472-6882-11-49.

5.

Calculating sample size in trials using historical controls.

Zhang S, Cao J, Ahn C.

Clin Trials. 2010 Aug;7(4):343-53. doi: 10.1177/1740774510373629. Epub 2010 Jun 23.

6.

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH.

Blood. 2010 Oct 7;116(14):2420-8. doi: 10.1182/blood-2010-05-285387. Epub 2010 Jun 10.

7.

Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.

Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ.

J Clin Oncol. 2010 Apr 10;28(11):1936-41. doi: 10.1200/JCO.2009.25.5489. Epub 2010 Mar 8.

8.

Phase II designs for anticancer botanicals and supplements.

Vickers AJ.

J Soc Integr Oncol. 2009 Winter;7(1):35-40.

9.

Targeting targeted agents: open issues for clinical trial design.

Bria E, Di Maio M, Carlini P, Cuppone F, Giannarelli D, Cognetti F, Milella M.

J Exp Clin Cancer Res. 2009 May 22;28:66. doi: 10.1186/1756-9966-28-66. Review.

10.

Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Plotkin SR, Halpin C, Blakeley JO, Slattery WH 3rd, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG 2nd.

J Neurooncol. 2009 May;93(1):61-77. doi: 10.1007/s11060-009-9867-7. Epub 2009 May 9. Review.

11.

Current issues in oncology drug development, with a focus on Phase II trials.

Sargent DJ, Taylor JM.

J Biopharm Stat. 2009;19(3):556-62. doi: 10.1080/10543400902802474.

12.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group.

J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.

13.

Recommended changes to oncology clinical trial design: revolution or evolution?

Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR, Stadler WM, Berry DA, Peck CC.

Eur J Cancer. 2008 Jan;44(1):8-11. Epub 2007 Nov 5. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk